此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

2012年2月21日 更新者:Sunovion

A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease

The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD

研究概览

详细说明

This was a double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel-group study of adult subjects with COPD. The study was double blinded through the use of both unit dose vial (UDV) and metered-dose inhaler (MDI) placebos, as appropriate. The primary efficacy analysis utilized the placebo control. Secondary analyses of the primary efficacy endpoint utilized the active control, and included comparisons between the placebo and active control. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

研究类型

介入性

注册 (实际的)

741

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Jasper、Alabama、美国、35501
        • Pulmonary & Sleep Associates of Jasper, PC
    • Arizona
      • Phoenix、Arizona、美国、85006
        • Pulmonary Associates, PA
      • Tucson、Arizona、美国、85712
        • Arizona Clinical Research Center, Inc.
    • California
      • Fair Oaks、California、美国、95628
        • Northern California Research Corp.
      • Fresno、California、美国、93720
        • SARC Research Center
      • Fullerton、California、美国、92835
        • California Research Medical Group, Inc.
      • Irvine、California、美国、92618
        • Radiant Research-Irvine
      • Newport Beach、California、美国
        • West Coast Clinical Trials
      • Paramount、California、美国、90723
        • Center for Clinical Trials, LLC
      • Rancho Mirage、California、美国、92270
        • Advances in Medicine
      • San Diego、California、美国、92120
        • Institute of HealthCare Assessment, Inc.
      • San Jose、California、美国
        • San Jose Clinical Research
      • Walnut Creek、California、美国、94598
        • Allergy & Asthma Medical Group of Diablo Valley, Inc.
    • Colorado
      • Denver、Colorado、美国、80218
        • Colorado Pulmonary Associates
      • Fort Collins、Colorado、美国
        • Northern Colorado Pulmonary Consultants, PC
    • Connecticut
      • Hartford、Connecticut、美国、06106
        • Physicians Research Center, Inc.
    • District of Columbia
      • Washington、District of Columbia、美国
        • Washington Hospital Center
    • Florida
      • Clearwater、Florida、美国、33765
        • Clinical Research of West Florida, Inc.
      • DeLand、Florida、美国、32720
        • University Clinical Research, DeLand
      • Miami Beach、Florida、美国、33140
        • Mt. Sinai Medical Center
      • Tampa、Florida、美国、33617
        • Clinical Pharmacology Services
    • Georgia
      • Austell、Georgia、美国、30106
        • Protocare Trial, Inc.
      • Marietta、Georgia、美国、30060
        • Marietta Pulmonary Medicine
    • Illinois
      • O'Fallon、Illinois、美国、62269
        • Office of Bradley Sakran, MD, PC
    • Indiana
      • South Bend、Indiana、美国、46617
        • South Bend Clinic
    • Kentucky
      • Louisville、Kentucky、美国、40215
        • Family Allergy & Asthma Research Institute
      • Somerset、Kentucky、美国
        • Cumberland Lung and Sleep Specialists
    • Louisiana
      • Lafayette、Louisiana、美国、70503
        • Bendel Medical Associates/Research
      • New Orleans、Louisiana、美国
        • New Orleans Center for Clinical Research
      • New Orleans、Louisiana、美国、70119
        • New Orleans Center for Clinical Research
      • New Orleans、Louisiana、美国、70115
        • Best Clinical Trials, LLC
      • Slidell、Louisiana、美国、70461
        • North Shore Research Associates
      • Sunset、Louisiana、美国、70584
        • Sunset Medical Research
    • Maryland
      • Baltimore、Maryland、美国
        • University of Maryland-Airways Research Center
      • Wheaton、Maryland、美国
        • Institute of Asthma and Allergy
    • Massachusetts
      • Boston、Massachusetts、美国、02135
        • Pro-Medica Clinical Research Center
    • Michigan
      • Ann Arbor、Michigan、美国、48106
        • ClinSite, Inc.
    • Missouri
      • Saint Louis、Missouri、美国、63108
        • Medex Healthcare Research, Inc.
      • St. Charles、Missouri、美国、63301-2847
        • Midwest Chest Consultants, PC
      • St. Louis,、Missouri、美国、63122
        • C.A.R.E Clinical Research
    • Montana
      • Butte、Montana、美国
        • Office of Keith Popovich, MD
      • Missoula、Montana、美国
        • Montana Medical Research, LLC
    • Nebraska
      • Omaha、Nebraska、美国
        • VA Medical Center
    • Nevada
      • Las Vegas、Nevada、美国、89119
        • Advanced Biomedical Research of America
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • Pulmonary Medicine
      • Charlotte、North Carolina、美国、28207
        • Charlotte Lung and Health Center
      • Statesville、North Carolina、美国、28625
        • Carolina Pharmaceutical Research, Inc.
      • Wilmington、North Carolina、美国、28412
        • New Hanover Medical Research
    • Ohio
      • Cincinnati、Ohio、美国、45241
        • New Horizons Clinical Research, Inc.
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73103
        • COR Clinical Research LLC
    • Oregon
      • Portland、Oregon、美国、97213
        • Allergy Associates Research Center
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18104
        • Northeast Clinical Research Centers, Inc.
      • Altoona、Pennsylvania、美国、16602
        • Keystone Clinical Solutions
      • Philadelphia、Pennsylvania、美国、19146
        • Philadelphia Health Associates - Adult Medicine
      • Ridley Park、Pennsylvania、美国、19078
        • Consortium Clinical Research, Ltd.
    • Rhode Island
      • East Providence、Rhode Island、美国、02914
        • Safe Harbor Clinical Research
    • South Carolina
      • Spartanburg、South Carolina、美国、29307
        • Spartanburg Pharmaceutical Research
    • Tennessee
      • Knoxville、Tennessee、美国、37920
        • Volunteer Research Group
    • Texas
      • Houston、Texas、美国、77084
        • Breath of Life Research Institute
      • New Braunfels、Texas、美国、78130
        • Central Texas Health Research
      • San Antonio、Texas、美国、78229
        • Sylvana Research Associates
    • Virginia
      • Fredericksburg、Virginia、美国、22401
        • Pulmonary Associates of Fredericksburg, Inc.
      • Richmond、Virginia、美国、23225
        • Pulmonary Associates of Richmond, Inc.
    • Washington
      • Bellingham、Washington、美国、98225
        • Bellingham Asthma, Allergy & Immunology Clinic
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • University of Wisconsin-Medical School

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

35年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Be willing to comply with study procedures and visit schedule
  • Are at least 35 years of age
  • Female subjects >65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization
  • Subjects of childbearing potential must be using an acceptable method of birth control. Female subjects who are considered not of childbearing potential must be: documented surgically sterile, OR postmenopausal.
  • Have a primary diagnosis of COPD. Diagnosis can be made during the screening process.
  • Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
  • Have a chest x-ray that is consistent with the diagnosis of COPD and taken <3 months prior to study start
  • Able to complete all study questionnaires and logs reliably

Exclusion Criteria:

  • Female subject who is pregnant or lactating
  • Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study
  • Subject whose schedule or travel prevents the completion of all required visits
  • Are scheduled for in-patient hospitalization, including elective surgery during the trial
  • Have life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days
  • History of asthma or any chronic respiratory disease other than COPD (chronic bronchitis and/or emphysema)
  • Have clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
  • Have a history of cancer except non-melanomatous skin cancer
  • Have a history of lung resection of more than one full lobe
  • Requires continuous supplemental oxygen therapy.
  • Has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
  • Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations
  • Have a history of substance abuse or drug abuse within 12 months, or with a positive urine drug screen
  • Are using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:1
Arformoterol 50 mcg QD and placebo MDI
arformoterol 50 mcg QD
其他名称:
  • (R,R)-福莫特罗
arformoterol 25 mcg BID
其他名称:
  • (R,R)-福莫特罗
arformoterol 15 mcg BID
其他名称:
  • 布罗瓦纳
  • (R,R)-福莫特罗
实验性的:2
Arformoterol 25 mcg BID and Placebo MDI
arformoterol 50 mcg QD
其他名称:
  • (R,R)-福莫特罗
arformoterol 25 mcg BID
其他名称:
  • (R,R)-福莫特罗
arformoterol 15 mcg BID
其他名称:
  • 布罗瓦纳
  • (R,R)-福莫特罗
实验性的:3
Arformoterol 15 mcg BID and placebo MDI
arformoterol 50 mcg QD
其他名称:
  • (R,R)-福莫特罗
arformoterol 25 mcg BID
其他名称:
  • (R,R)-福莫特罗
arformoterol 15 mcg BID
其他名称:
  • 布罗瓦纳
  • (R,R)-福莫特罗
有源比较器:4
Salmeterol MDI 42 mcg BID and placebo inhalation solution
Salmeterol MDI 42 mcg BID
其他名称:
  • Serevent MDI
安慰剂比较:5
Placebo MDI and placebo inhalation solution
安慰剂出价

研究衡量的是什么?

主要结果指标

结果测量
大体时间
percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period.
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12

次要结果测量

结果测量
大体时间
预测 FEV1 的峰值百分比
大体时间:第 -2、0、3、6、9、12 周
第 -2、0、3、6、9、12 周
time-normalized area under the percent change from visit predose curve for FEV1 over 12 hours (nAUC0-12-P)
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
time-normalized area under the percent change in FEV1 from study baseline over 12 hours (nAUC0-12-B)
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
time-normalized area under the percent change from visit predose curve for FEV1 over 24 hours (nAUC0-24-P)
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
time-normalized area under the percent change in FEV1 from study baseline curve over 24 hours (nAUC0-24-B)
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
peak percent change in FEV1 from visit predose and study baseline
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
time point changes in FEV1; time to onset of response
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
time to peak change in FEV1
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
at-home and in-clinic peak expiratory flow rate (PEFR)
大体时间:Weeks -2, 0, 3, 6, 9, 12
Weeks -2, 0, 3, 6, 9, 12
relationship between the plasma concentration values and selected pharmacodynamic parameters
大体时间:Weeks -2, 0, 3, 6, 9, 12, 13
Weeks -2, 0, 3, 6, 9, 12, 13
Supplemental ipratropium bromide MDI and racemic albuterol MDI use
大体时间:Weeks 0-13
Weeks 0-13
COPD exacerbations and COPD symptom ratings
大体时间:Weeks 0-13
Weeks 0-13
St. George's Hospital Respiratory Questionnaire
大体时间:Weeks 0, 6, 13
Weeks 0, 6, 13
Investigator and Subject Global Evaluations
大体时间:Weeks -2, 12, 13
Weeks -2, 12, 13
Baseline and Transitional Dyspnea Index
大体时间:Weeks -2, 6, 12
Weeks -2, 6, 12
distance walked in six minutes
大体时间:Weeks -2, 3, 9
Weeks -2, 3, 9

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2002年4月1日

初级完成 (实际的)

2004年3月1日

研究完成 (实际的)

2004年3月1日

研究注册日期

首次提交

2003年7月8日

首先提交符合 QC 标准的

2003年7月8日

首次发布 (估计)

2003年7月9日

研究记录更新

最后更新发布 (估计)

2012年2月22日

上次提交的符合 QC 标准的更新

2012年2月21日

最后验证

2012年2月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅